Trading Signals: MYGN Stock Price Prediction and Forecast (Mon. Oct. 26, 2015 - Wed. Sep. 27, 2023)(Myriad Genetics, Inc. )
| MYGN latest price $29.7200 (1.3%) ($29.1500 - $29.7200) on Fri. Jun. 11, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.52% (three month average) | RSI | 65 | Latest Price | $29.7200(1.3%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | MYGN advances 1.6% a day on average for past five trading days. | Weekly Trend | MYGN advances 2.2% a week on average for past two weeks. | Market Behavior | Normal for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support MYGN advance at 0% a week (0% probability) IWO(57%) IWM(55%) IBB(53%) IWC(52%) FIVG(50%) | Factors Impacting MYGN price | MYGN will decline at least -1.76% in a week (0% probabilities). VIXM(-29%) UUP(-22%) VXX(-15%) TBT(-7%) UNG(1%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.76% (StdDev 3.52%) | Hourly BBV | 0.6 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $29.51(0.71%) | 10 Day Moving Average | $28.75(3.37%) | 20 Day Moving Average | $28.31(4.98%) | To recent high | -6.1% | To recent low | 17.2% | Market Cap | $2.22b | | | | Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to asses an individual's risk of developing a disease later in life. The Other segment offers products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients; and also includes corporate services such as finance, human resources, legal, and information technology. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT. |